论文部分内容阅读
[目的]观察中药复方制剂肺泰胶囊联合化疗对晚期非小细胞肺癌“气虚痰瘀互结证”患者的临床疗效。[方法]将60例晚期非小细胞肺癌患者随机分为治疗组和对照组各30例,治疗组给予肺泰胶囊联合化疗,对照组给予单纯化疗。观察用药后两组瘤体指标、临床症状、生活质量、免疫功能变化等情况。[结果]治疗组和对照组瘤体稳定率分别60.0%和51.7%(P=0.522);临床症状改善总有效率分别为73.3%和41.4%(P=0.05);两组的卡氏评分提高稳定率分别为83.4%和58.6%(P=0.013);治疗组治疗后CD3、CD4、CD4/CD8较对照组明显升高(P<0.05,P<0.01),治疗组CD8较对照组明显降低(P<0.01)。[结论]肺泰胶囊能明显改善晚期非小细胞肺癌“气虚痰瘀互结证”患者临床症状和生活质量,提高免疫功能。
[Objective] To observe the clinical curative effect of traditional Chinese medicine compound preparation of lung-tai capsule combined with chemotherapy on patients with advanced non-small cell lung cancer and Qi-deficiency, phlegm and blood stasis. [Method] 60 cases of advanced non-small cell lung cancer were randomly divided into treatment group and control group, 30 cases in each group. The treatment group was treated with combination of lungtai capsule and the control group with chemotherapy alone. Observed after treatment two groups of tumor indicators, clinical symptoms, quality of life, changes in immune function and so on. [Results] The tumor stabilization rates in treatment group and control group were 60.0% and 51.7%, respectively (P = 0.522). The total effective rate of clinical symptom improvement was 73.3% and 41.4% respectively (P = 0.05) The levels of CD3, CD4 and CD4 / CD8 in the treatment group were significantly higher than those in the control group (P <0.05, P <0.01). The CD8 in the treatment group was significantly lower than that in the control group (P <0.01). [Conclusion] Fei Tai Capsule can significantly improve the clinical symptoms and quality of life of patients with advanced non-small cell lung cancer, Qi-deficiency, phlegm and blood stasis syndrome, and improve immune function.